EA201992349A1 - Fgfr3-связывающие молекулы - Google Patents
Fgfr3-связывающие молекулыInfo
- Publication number
- EA201992349A1 EA201992349A1 EA201992349A EA201992349A EA201992349A1 EA 201992349 A1 EA201992349 A1 EA 201992349A1 EA 201992349 A EA201992349 A EA 201992349A EA 201992349 A EA201992349 A EA 201992349A EA 201992349 A1 EA201992349 A1 EA 201992349A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amino acid
- seq
- acid sequence
- conservative
- acid positions
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 17
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к полипептиду, связывающемуся с изоформами 3b и 3c рецептора 3 фактора роста фибробластов (FGFR3b и FGFR3c), где полипептид содержит аминокислотную последовательность, выбранную из группы, состоящей из (a) GVTLFVALYDYEVYGPTPMLSFHKGEKFQIL(X)(X)(X)(X)GPYWEARSL(X)TGETG(X)IPSNYVAPVDSIQ (SEQ ID NO: 1), где аминокислотные положения от (X) до (X) могут представлять собой любую аминокислотную последовательность; (b) аминокислотной последовательности, которая по меньшей мере на 95% идентична аминокислотной последовательности из (a), где при определении идентичности исключаются аминокислотные положения от (X) до (X) и при условии, что аминокислотная последовательность EVYGPTPM (SEQ ID NO: 2) в аминокислотных положениях 12-19 из SEQ ID NO: 1 является консервативной и аминокислоты P и Y в аминокислотных положениях 37 и 38 из SEQ ID NO: 1 являются консервативными; (c) GVTLFVALYDYEVMSTTALSFHKGEKF QILSQSPHGQYWEARSLTTGETG(X)IPSNYVAPVDSIQ (SEQ ID NO: 19), где аминокислотное положение (X) может представлять собой любую аминокислоту; (d) аминокислотной последовательности, которая по меньшей мере на 95% идентична аминокислотной последовательности из (c), где при определении идентичности исключается аминокислотное положение (X) и при условии, что аминокислотные последовательности EVMSTTA (SEQ ID NO: 20) в аминокислотных положениях 12-18 из SEQ ID NO: 19 и SQSPH (SEQ ID NO: 21) в аминокислотных положениях 31-35 из SEQ ID NO: 19 являются консервативными и аминокислоты Q и Y в аминокислотных положениях 37 и 38 из SEQ ID NO: 19 являются консервативными.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164482 | 2017-04-03 | ||
PCT/EP2018/058390 WO2018185050A1 (en) | 2017-04-03 | 2018-04-03 | Fgfr3 binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992349A1 true EA201992349A1 (ru) | 2020-02-17 |
Family
ID=58606015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992349A EA201992349A1 (ru) | 2017-04-03 | 2018-04-03 | Fgfr3-связывающие молекулы |
Country Status (19)
Country | Link |
---|---|
US (2) | US10722589B2 (ru) |
EP (1) | EP3606953B1 (ru) |
JP (1) | JP6840907B2 (ru) |
KR (1) | KR20190137831A (ru) |
CN (1) | CN110536904A (ru) |
AU (1) | AU2018247801B2 (ru) |
BR (1) | BR112019019666A2 (ru) |
CA (1) | CA3056362A1 (ru) |
DK (1) | DK3606953T3 (ru) |
EA (1) | EA201992349A1 (ru) |
ES (1) | ES2883377T3 (ru) |
HR (1) | HRP20211096T1 (ru) |
HU (1) | HUE054869T2 (ru) |
IL (1) | IL269752B (ru) |
LT (1) | LT3606953T (ru) |
NZ (1) | NZ757365A (ru) |
SG (1) | SG11201909252XA (ru) |
SI (1) | SI3606953T1 (ru) |
WO (1) | WO2018185050A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113039271A (zh) * | 2018-10-02 | 2021-06-25 | 田边三菱制药株式会社 | 靶向黏结蛋白聚糖-1和成纤维细胞生长因子受体的双特异性结合剂 |
CN114716548A (zh) * | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Il‐2レセプター特異的キメラ抗体 |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE60233509D1 (de) | 2001-06-20 | 2009-10-08 | Fibron Ltd | Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon |
IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
CA2595398A1 (en) | 2004-11-04 | 2006-05-11 | Fibron Limited | Treatment of b-cell malignancies |
WO2007144893A2 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
HUE061117T2 (hu) | 2009-03-25 | 2023-05-28 | Genentech Inc | Anti-FGFR3 antitestek és eljárások alkalmazásukra |
NZ598351A (en) | 2009-08-27 | 2014-08-29 | Covagen Ag | Il-17 binding compounds and medical uses thereof |
KR20140135251A (ko) | 2012-03-16 | 2014-11-25 | 코바겐 아게 | 항종양 활성이 있는 신규 결합 분자 |
EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
MX2015014608A (es) * | 2013-04-19 | 2016-03-03 | Covagen Ag | Novedosas moleculas de union biespecifica con actividad antitumoral. |
BR112016021083A2 (pt) | 2014-03-17 | 2017-10-03 | Mitsubishi Tanabe Pharma Corp | Conjugados anticorpo-fynomer |
-
2018
- 2018-04-02 US US15/943,137 patent/US10722589B2/en active Active
- 2018-04-03 SI SI201830352T patent/SI3606953T1/sl unknown
- 2018-04-03 JP JP2019569749A patent/JP6840907B2/ja active Active
- 2018-04-03 LT LTEP18714525.5T patent/LT3606953T/lt unknown
- 2018-04-03 AU AU2018247801A patent/AU2018247801B2/en not_active Ceased
- 2018-04-03 CA CA3056362A patent/CA3056362A1/en active Pending
- 2018-04-03 HU HUE18714525A patent/HUE054869T2/hu unknown
- 2018-04-03 DK DK18714525.5T patent/DK3606953T3/da active
- 2018-04-03 BR BR112019019666A patent/BR112019019666A2/pt not_active IP Right Cessation
- 2018-04-03 NZ NZ757365A patent/NZ757365A/en not_active IP Right Cessation
- 2018-04-03 SG SG11201909252X patent/SG11201909252XA/en unknown
- 2018-04-03 CN CN201880022181.4A patent/CN110536904A/zh active Pending
- 2018-04-03 ES ES18714525T patent/ES2883377T3/es active Active
- 2018-04-03 EA EA201992349A patent/EA201992349A1/ru unknown
- 2018-04-03 WO PCT/EP2018/058390 patent/WO2018185050A1/en unknown
- 2018-04-03 EP EP18714525.5A patent/EP3606953B1/en active Active
- 2018-04-03 KR KR1020197031642A patent/KR20190137831A/ko not_active Application Discontinuation
-
2019
- 2019-10-02 IL IL269752A patent/IL269752B/en active IP Right Grant
-
2020
- 2020-06-15 US US16/901,160 patent/US11351267B2/en active Active
-
2021
- 2021-07-09 HR HRP20211096TT patent/HRP20211096T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BR112019019666A2 (pt) | 2020-04-22 |
DK3606953T3 (da) | 2021-08-16 |
IL269752B (en) | 2020-03-31 |
WO2018185050A1 (en) | 2018-10-11 |
AU2018247801A1 (en) | 2019-09-26 |
US11351267B2 (en) | 2022-06-07 |
JP2020518279A (ja) | 2020-06-25 |
HRP20211096T1 (hr) | 2021-10-15 |
US10722589B2 (en) | 2020-07-28 |
KR20190137831A (ko) | 2019-12-11 |
CN110536904A (zh) | 2019-12-03 |
SI3606953T1 (sl) | 2021-10-29 |
NZ757365A (en) | 2022-07-01 |
EP3606953A1 (en) | 2020-02-12 |
US20180280527A1 (en) | 2018-10-04 |
SG11201909252XA (en) | 2019-11-28 |
LT3606953T (lt) | 2021-08-10 |
US20200345859A1 (en) | 2020-11-05 |
ES2883377T3 (es) | 2021-12-07 |
HUE054869T2 (hu) | 2021-10-28 |
AU2018247801B2 (en) | 2020-02-20 |
IL269752A (en) | 2019-11-28 |
JP6840907B2 (ja) | 2021-03-10 |
CA3056362A1 (en) | 2018-10-11 |
EP3606953B1 (en) | 2021-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792651A1 (ru) | Аденовирусные полинуклеотиды и полипептиды | |
UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
EA201890220A1 (ru) | Вакцина против rsv | |
FI3256579T3 (fi) | Kysteiiniproteaasi | |
EA201790934A1 (ru) | ВАРИАНТЫ ИНТЕРФЕРОНА α2b | |
DE602005020165D1 (de) | Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin | |
RU2014150224A (ru) | Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов | |
RS52537B (en) | ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT | |
EA201792362A1 (ru) | Композиции и способы для лечения целиакии спру | |
EA201590611A1 (ru) | Новые молекулы, связывающие il-17a, и их медицинское применение | |
PL415888A1 (pl) | Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie | |
WO2017032856A3 (en) | Compounds for inducing tissue formation and uses thereof | |
EA201992349A1 (ru) | Fgfr3-связывающие молекулы | |
JP2019500414A5 (ru) | ||
BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
MX2020010716A (es) | Metodo para escindir de la fase solida peptidos unidos a una fase solida. | |
PH12017550134A1 (en) | Il-37 variants | |
MY187334A (en) | Xylanase | |
BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
PH12018500468A1 (en) | Fusion protein | |
MX2020010422A (es) | Alfa-amilasa maltogenica variante. | |
MX2017013480A (es) | Composicion farmaceutica para tratar y/o prevenir el cancer. | |
EA202092963A1 (ru) | Новый белок с противовоспалительными свойствами | |
MX2020007336A (es) | Metodos y composiciones para modular la disfuncion de celulas endoteliales. | |
MX2022007237A (es) | Variante del virus de la vacuna oncolitica y metodos de uso del mismo. |